Recent News

• 01.20.2026 - Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
• 01.20.2026 - Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
• 01.16.2026 - Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
• 01.16.2026 - Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
• 01.16.2026 - Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
• 01.16.2026 - Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
• 01.09.2026 - Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
• 01.09.2026 - Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
• 12.29.2025 - Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
• 12.29.2025 - Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Recent Filings

• 01.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.16.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.16.2026 - EX-99.1 EX-99.1
• 01.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.16.2026 - EX-99.1 EX-99.1
• 01.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.09.2026 - EX-99.1 EX-99.1
• 12.29.2025 - EX-99.1 EX-99.1
• 12.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]